![Georgios Trichas](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Georgios Trichas
Profile
Georgios Trichas worked as a Director at Acesion Pharma ApS and as a Business Analyst at Wellcome Trust Ltd.
(Direct Investments).
He graduated from the University of Oxford and the University of Crete.
Former positions of Georgios Trichas
Companies | Position | End |
---|---|---|
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Director/Board Member | - |
Wellcome Trust Ltd. (Direct Investments)
![]() Wellcome Trust Ltd. (Direct Investments) Investment ManagersFinance Wellcome Trust Ltd. Direct Investments (WTDI) is a private equity and venture capital division of the Wellcome Trust Ltd. The firm was founded in 1936 by Sir Henry Wellcome. It’s headquartered in London, UK. | Private Equity Analyst | - |
Training of Georgios Trichas
University of Crete | Graduate Degree |
University of Oxford | Graduate Degree |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Wellcome Trust Ltd. (Direct Investments)
![]() Wellcome Trust Ltd. (Direct Investments) Investment ManagersFinance Wellcome Trust Ltd. Direct Investments (WTDI) is a private equity and venture capital division of the Wellcome Trust Ltd. The firm was founded in 1936 by Sir Henry Wellcome. It’s headquartered in London, UK. | Finance |
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Stock Market
- Insiders
- Georgios Trichas